Home About us Contact
|
Home About us Contact | ||
|
|
||
Tumour Immunity (tumour + immunity)
Selected AbstractsRegulatory T cells and tumour immunity , observations in mice and menIMMUNOLOGY, Issue 2 2008Awen Gallimore Summary An enormous body of work supports a role for CD4+ CD25+ regulatory cells (Tregs) in shaping the immune response to tumours. Indeed, there is evidence that the cells impede effective tumour immunosurveillance, inhibit vaccine-induced antitumour immune responses and promote tumour progression. Studies exploring the impact of Tregs on tumour development are discussed in the context of manipulating this T-cell population for the purpose of cancer immunotherapy. [source] Regulation of tumour immunity by CD25+ T cellsIMMUNOLOGY, Issue 1 2002Awen Gallimore First page of article [source] Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunityCLINICAL & EXPERIMENTAL IMMUNOLOGY, Issue 2 2006R. Kim Summary Dendritic cells play a crucial role in initiating tumour immunity as well as in the immune response for invading foreign pathogens such as bacteria and viruses. For bacterial and viral infections, the immature dendritic cells (iDCs) residing in peripheral tissues are efficiently activated and matured by pathogen signals for performing the immune response. In contrast, for self-antigens, the naive T cells are not activated by iDCs but proceed to anergy/deletion, and the generation of regulatory T cells for immune tolerance. The induction of immune response and tolerance is regulated strictly by iDCs as the sensor for homeostasis of immune response in the host. Despite the identification of some tumour antigens, tumour immunity is not provoked successfully. Even though there are some critical obstacles to inhibit effective tumour immunity, tumour cells are able to exploit the functional roles of iDCs for tumour progression, which are induced by tumour-derived soluble factors such as vascular endothelial growth factor (VEGF) and functionally modulated in the microenvironment. The iDCs still remain as the critical target for provoking tumour immunity. In this review, the functional roles of tumour-associated iDCs and the strategy for targeting iDCs in effective tumour immunity for the cancer patient are discussed. [source] Interleukins 7 and 12 are expressed in head and neck squamous cancerCLINICAL OTOLARYNGOLOGY, Issue 4 2001V. Paleri paleri v., pulimood a., davies g.r. &birchall m.a. (2001) Clin. Otolaryngol.26, 302,306 Interleukins 7 and 12 are expressed in head and neck squamous cancer Interleukin 7 (IL-7) and IL-12 have major roles in cell-mediated tumour immunity. In head and neck squamous cell cancer, depressed cell-mediated immunity is well documented and may account for the poor prognosis. This is the first study to assess intratumour expression of IL-7 and IL-12 in head and neck squamous cell cancer (HNSCC). Immunohistochemistry was used to identify IL-7 and IL-12 expression in snap-frozen tumour specimens from 25 patients with HNSCC and the results of immunohistochemical staining were semiquantitatively graded. Both IL-7 and IL-12 were expressed in all tumour samples and expression was not related to tumour stage or site. A trend towards better survival was associated with high expression of IL-7 and IL-12, this being more pronounced with IL 7. The universal expression suggests that the depressed cell-mediated immunity in HNSCC is not caused by reduced production of IL-7 and IL-12. Further studies with larger cohorts, especially of IL-7, are certainly warranted. [source] | ||||||||||